Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis
详细信息 查看全文
- 作者：Fré ; dé ; ric Sedela ; frederic.sedel@medday-pharma.com" class="auth_mail" title="E-mail the corresponding author ; Delphine Bernarda ; delphine.bernard@medday-pharma.com" class="auth_mail" title="E-mail the corresponding author ; Donald M. Mockb ; c ; MockDonaldM@uams.edu" class="auth_mail" title="E-mail the corresponding author ; Ayman Tourbahd ; atourbah@chu-reims.fr" class="auth_mail" title="E-mail the corresponding author
- 关键词：Multiple sclerosis ; Biotin ; Promyelinogenic agent ; Virtual hypoxia
- 刊名：Neuropharmacology
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：110
- 期：part_PB
- 页码：644-653
- 全文大小：1116 K
文摘
- •
High-dose biotin is a promising novel treatment for progressive multiple sclerosis.
- •
300 mg biotin daily improved MS-related disability in an open-label study.
- •
Biotin is essential for fatty acid synthesis and energy production.
- •
High-dose biotin may promote axonal remyelination by enhancing myelin production.
- •
High-dose biotin may also reduce axonal hypoxia through enhanced energy production.